BMS Says Its New CAR-T Worked. It Just Won't Say How Well.
BMS's new GPRC5D-targeting CAR-T therapy met all its pivotal trial endpoints in multiple myeloma. But in an unusual move, the company refused to share the actual response rates. In a crowded CAR-T race, what you don't say can be louder than what you do.
The Dog That Caught the Car
Imagine training for a marathon for three years, crossing the finish line, and then refusing to tell anyone your time. That's essentially what Bristol Myers Squibb just did with its newest CAR-T therapy for multiple myeloma.
On Thursday, BMS announced that arlo-cel (arlocabtagene autoleucel), its GPRC5D-targeting CAR-T cell therapy, met its primary endpoint in the registrational Phase 2 QUINTESSENTIAL trial. The company also said it hit key secondary endpoints. Good news, right? In theory, yes. But there's a catch that has analysts scratching their heads.
BMS's initial announcement highlighted that the results were "statistically significant and clinically meaningful," with the full dataset reserved for a future medical conference. While the company did share specific response-rate figures in associated investor materials, the headline press release kept the focus on topline conclusions rather than detailed numbers. For a registrational trial (the kind designed to support an FDA filing), that approach is unusual enough to raise eyebrows across the industry.
What We Know, and What We Don't
Let's start with what BMS did say. The QUINTESSENTIAL trial tested arlo-cel in patients with relapsed or refractory multiple myeloma who were "quadruple-class exposed," meaning their cancer had already shrugged off four different types of treatment. These are patients running out of options. The primary endpoint was overall response rate (ORR), which measures the percentage of patients whose cancer shrank meaningfully after treatment.
BMS confirmed the trial met that primary endpoint. It also met secondary endpoints, including complete response rate (CRR) in patients with four or more prior lines of therapy, plus ORR and CRR in a slightly broader group with three or more prior treatments. All encouraging signals.
This matters because numbers are how investors, doctors, and competing companies evaluate a therapy. Saying a trial "met its endpoint" is like saying a restaurant "has food." Technically true, but not particularly helpful when you're trying to decide where to eat.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Earlier Data Painted a Rosy Picture
The frustrating part is that arlo-cel's earlier results were genuinely impressive. In Phase 1, the therapy showed an 87% overall response rate with a 53% complete response rate across evaluable patients. At the recommended Phase 2 dose, those numbers ticked up to 91% ORR and 48% CR.
In an even smaller cohort of patients treated earlier in their disease course (one to three prior lines of therapy), researchers reported a 96% ORR and 67% complete response rate. Those are the kind of numbers that make oncologists sit up straight.
So the Phase 2 registrational trial was supposed to confirm what Phase 1 strongly suggested: that arlo-cel works, and it works well. The fact that BMS isn't sharing the specifics prominently yet could mean several things, and not all of them are bad.
Why Would a Company Play Coy?
There are a few possible explanations, ranging from innocent to strategic to slightly worrying.
The most charitable read: BMS wants to save the full data reveal for a high-profile medical meeting, where it can present the complete picture (including durability data, safety profiles, and subgroup analyses) in one polished package. This happens in biotech. Companies sometimes hold back topline numbers to maximize the impact of a conference presentation. Think of it as a movie studio refusing to show the full trailer before the premiere.
The more strategic read: BMS might be trying to control the narrative in a competitive space that's getting crowded fast. If the numbers are good but not spectacular compared to earlier Phase 1 data, releasing them raw could invite unflattering snap comparisons. Better to present them in context at a conference where the full story can be told.
The concerning read: the numbers might be softer than hoped. Response rates in registrational trials sometimes come in lower than Phase 1 results, because the patient population is larger, more diverse, and more rigorously defined. If arlo-cel's ORR dropped meaningfully from that 87-91% Phase 1 range, BMS might prefer to soften the landing with a controlled data release rather than a headline-grabbing topline miss.
We simply don't know yet. And that's the problem.
The Competitive Chess Match Behind the Curtain
Arlo-cel isn't just any CAR-T. It targets GPRC5D, a protein found on myeloma cells that's different from BCMA, the target used by the two CAR-T therapies already approved for multiple myeloma: BMS's own Abecma and Johnson & Johnson/Legend Biotech's Carvykti.
Why does the target matter? Because many myeloma patients are now being treated with BCMA-directed therapies first. When they relapse (and unfortunately, many do), they need something that attacks the cancer through a different door. GPRC5D is that door. It's expressed on myeloma cells but has limited presence in healthy tissue, making it an attractive target for the post-BCMA world.
This makes arlo-cel strategically critical for BMS. The company's myeloma playbook appears to be a BCMA-to-GPRC5D sequence: treat patients with Abecma first, then follow up with arlo-cel when the cancer comes back. If it works, BMS could own two sequential chapters of a patient's treatment journey rather than just one.
But they're not alone in this space. Janssen (J&J's pharma arm) already has an approved GPRC5D-directed bispecific antibody, talquetamab (TALVEY), which received FDA accelerated approval in 2023. Legend Biotech is exploring dual-target CAR-T approaches that combine GPRC5D with other targets. And the bispecific antibody category broadly is growing fast because those drugs are "off-the-shelf" treatments; they don't require the weeks-long manufacturing process that CAR-T demands.
The Bigger Picture: CAR-T vs. Bispecifics
The myeloma treatment landscape is undergoing a quiet revolution. BCMA CAR-T still leads the market commercially, with Carvykti projected to hold roughly 37% of the CAR-T market share in 2026. But bispecific antibodies are gaining ground because they're far easier to administer.
CAR-T therapy is like custom-building a sports car for each patient. Doctors extract a patient's immune cells, ship them to a manufacturing facility, genetically engineer them to attack cancer, grow millions of copies, and infuse them back into the patient. The process takes weeks and requires specialized treatment centers. It's powerful, but it's logistically demanding.
Bispecific antibodies, by contrast, are more like a rental car. They come ready to use, no customization required. For patients who can't wait weeks for their cells to be manufactured, or who don't live near a certified treatment center, bispecifics can be the more practical option.
The competitive question for arlo-cel, then, is twofold. First: are the efficacy numbers strong enough to justify the complexity of CAR-T manufacturing? And second: can it differentiate itself in the post-BCMA space where bispecifics are also making moves?
BMS apparently thinks the answers to both questions are yes. But without the prominently released data, the market is left guessing.
A Transparency Problem, or Business as Usual?
It's worth noting that companies can legally withhold pre-approval trial data. The FDA treats efficacy information from unapproved applications as confidential, and there's no regulatory requirement for sponsors to share topline numbers in a press release. Some companies do it as a courtesy to investors; others don't.
But "legally permissible" and "good practice" aren't the same thing. At the registrational stage, when a therapy is one step away from an FDA filing, transparency matters more than ever. Patients are making treatment decisions. Investors are allocating capital. Competitors are calibrating their own strategies. Withholding the numbers creates an information vacuum that gets filled by speculation.
The biotech industry has a long, complicated relationship with selective disclosure. Companies routinely trumpet positive headlines while burying the details that provide context. BMS's move isn't unprecedented, but the combination of a pivotal trial, a competitive target, and the limited prominence of efficacy figures in its announcement does feel like it's pushing the boundary of what's considered normal.
What Happens Next
BMS has said the full results will be presented at a future medical meeting, with the company's own timeline pointing to 2026 for the full data presentation. The most likely venues are ASH (the American Society of Hematology's annual meeting) or a similar high-profile oncology conference.
When those numbers finally drop, the market will be watching for a few things. Does the registrational ORR hold up compared to the 87-91% range from Phase 1? Are the complete response rates deep enough to suggest durable benefit? And how does the safety profile look in a larger, more diverse patient population?
For now, arlo-cel's QUINTESSENTIAL trial has been officially de-risked. The endpoints were met. The program moves forward. But in a world where data is currency, BMS chose to keep its wallet closed. The question everyone is asking: what's in there that they don't want us to see yet?
Or maybe the better question: what's in there that they want to show us on their terms?
Deals & M&A5 min read
Novartis Just Had Its Worst Month in Years. Now Shareholders Want Heads to Roll.
A major Novartis shareholder is demanding a board overhaul after back-to-back trial failures and a record stock drop. When your $12 billion acquisition produces a drug that flunks its biggest test, someone has to answer for it.
